Kodiak Sciences Inc

Quick facts

Phase 3 pipeline

• KSI-101 · Ophthalmology
  KSI-101 is a bispecific antibody that simultaneously targets VEGF and ANG-2 to reduce retinal inflammation and vascular leakage in retinal diseases.
• Tabirafusp tedromer · Allergy
  Tabirafusp tedromer is a fusion protein that targets the interleukin-4 receptor alpha subunit.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Kodiak Sciences Inc portfolio CI brief
• Kodiak Sciences Inc pipeline updates RSS